RESUMEN
We performed a detailed ultrastructural reconstruction of the "passive" miracidium of Derogenes varicus Muller, 1784 , a species from the Hemiurata group. The miracidium is highly miniaturized and simplified in comparison with the "active" miracidia. For the first time we elucidated the nature of the spines on the surface of the hemiuroid larva: they are derivatives of the epithelial plates. The anterior end of the larva is equipped with three epithelial plates that bear both spines and cilia. The major part of the miracidial surface is formed by the tegument. The nervous and excretory systems of the D. varicus miracidium are extremely reduced. Single undifferentiated cell comprises the germinal material of the miracidium. We discuss the trends of evolution of hemiuroid miracidia that are associated with the transition to passive strategy of infection.
RESUMEN
TTK protein kinase (TTK), also known as Monopolar spindle 1 (MPS1), is a key regulator of the spindle assembly checkpoint (SAC), which functions to maintain genomic integrity. TTK has emerged as a promising therapeutic target in human cancers, including triple-negative breast cancer (TNBC). Several TTK inhibitors (TTKis) are being evaluated in clinical trials, and an understanding of the mechanisms mediating TTKi sensitivity and resistance could inform the successful development of this class of agents. We evaluated the cellular effects of the potent clinical TTKi CFI-402257 in TNBC models. CFI-402257 induced apoptosis and potentiated aneuploidy in TNBC lines by accelerating progression through mitosis and inducing mitotic segregation errors. We used genome-wide CRISPR/Cas9 screens in multiple TNBC cell lines to identify mechanisms of resistance to CFI-402257. Our functional genomic screens identified members of the anaphase-promoting complex/cyclosome (APC/C) complex, which promotes mitotic progression following inactivation of the SAC. Several screen candidates were validated to confer resistance to CFI-402257 and other TTKis using CRISPR/Cas9 and siRNA methods. These findings extend the observation that impairment of the APC/C enables cells to tolerate genomic instability caused by SAC inactivation, and support the notion that a measure of APC/C function could predict the response to TTK inhibition. Indeed, an APC/C gene expression signature is significantly associated with CFI-402257 response in breast and lung adenocarcinoma cell line panels. This expression signature, along with somatic alterations in genes involved in mitotic progression, represent potential biomarkers that could be evaluated in ongoing clinical trials of CFI-402257 or other TTKis.
Asunto(s)
Ciclosoma-Complejo Promotor de la Anafase/metabolismo , Proteínas de Ciclo Celular/antagonistas & inhibidores , Resistencia a Antineoplásicos , Inhibidores de Proteínas Quinasas/farmacología , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Pirazoles/farmacología , Pirimidinas/farmacología , Neoplasias de la Mama Triple Negativas/enzimología , Ciclosoma-Complejo Promotor de la Anafase/genética , Proteínas de Ciclo Celular/metabolismo , Línea Celular Tumoral , Femenino , Inestabilidad Genómica/efectos de los fármacos , Humanos , Mitosis/efectos de los fármacos , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Tirosina Quinasas/metabolismo , Neoplasias de la Mama Triple Negativas/tratamiento farmacológico , Neoplasias de la Mama Triple Negativas/genética , Neoplasias de la Mama Triple Negativas/fisiopatologíaRESUMEN
BACKGROUND: Alexithymia refers to difficulty in identifying and expressing emotions. Alexithymia is associated with high burden of disease in patients with psoriasis. OBJECTIVES: To investigate whether alexithymia was reversible in patients with psoriasis following real-life therapeutic intervention. METHODS: The Epidemiological Study in Patients with Recently Diagnosed Psoriasis (EPIDEPSO; NCT01964443) was a 1-year multicentre observational study investigating the prevalence of alexithymia and other psychosocial comorbidities in patients with psoriasis with ≤ 10 years' disease duration and eligible for systemic treatment. Alexithymia was assessed using the Toronto Alexithymia Scale (TAS-20) at baseline, 6 months and 1 year. RESULTS: There was a statistically significant decrease in the prevalence of alexithymia in the follow-up cohort, from 26·7% at baseline to 21·2% at 6 months and 18·8% at 1 year. More than half of the patients (n = 77, 53·8%) who were alexithymic at baseline experienced reversion of their alexithymia. Reversion of alexithymia was higher in patients who reached a high level of disease control, defined as ≥ 75% or ≥ 90% improvement in Psoriasis Area and Severity Index. Reversion of alexithymia was associated with dramatic improvement in quality of life, anxiety and depression. Moreover, hazardous alcohol use, highly prevalent in patients with alexithymia, was reduced almost threefold at 1 year. CONCLUSIONS: Alexithymia and associated high disease burden may be reversible in patients with effective treatment of psoriasis. Proactive recognition of patients who are unable to identify and express their feelings is important.
Asunto(s)
Síntomas Afectivos/epidemiología , Costo de Enfermedad , Fármacos Dermatológicos/uso terapéutico , Psoriasis/tratamiento farmacológico , Calidad de Vida , Adulto , Síntomas Afectivos/diagnóstico , Síntomas Afectivos/psicología , Ansiedad/diagnóstico , Ansiedad/epidemiología , Ansiedad/psicología , Comorbilidad , Depresión/diagnóstico , Depresión/epidemiología , Depresión/psicología , Femenino , Estudios de Seguimiento , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Medición de Resultados Informados por el Paciente , Prevalencia , Psoriasis/diagnóstico , Psoriasis/epidemiología , Psoriasis/psicología , Pruebas Psicológicas/estadística & datos numéricos , Autoinforme/estadística & datos numéricos , Índice de Severidad de la Enfermedad , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND: Single-centre studies show that alexithymia, defined as difficulty in recognizing and describing emotions, is more prevalent among patients with psoriasis than in the general population. However, its prevalence and the consequences of the association between alexithymia and psoriasis are unclear. OBJECTIVES: The primary objective of this study was to determine the prevalence of alexithymia, as defined by a score ≥ 61 in the 20-item Toronto Alexithymia Scale, in a large sample of patients who had plaque psoriasis for ≤ 10 years and were eligible for phototherapy or systemic treatment. The secondary objectives were to investigate the relationship between alexithymia and the clinical and psychological aspects of psoriasis. METHODS: Data were collected in the framework of an observational, multicentre, international study, the EPidemiological Study In Patients With Recently DiagnosEd PSOriasis (EPIDEPSO), aiming at investigating the prevalence of alexithymia and other psychosocial comorbidities in patients with psoriasis of ≤ 10 years' disease duration. RESULTS: The prevalence of alexithymia within a cohort of 670 patients was 24·8% (95% confidence interval 21·7-28·2). Patients with alexithymia had a higher burden of psoriasis, including significant impairment of quality of life, higher levels of anxiety and depression, a higher risk of alcohol dependency and impairment of work productivity, compared with patients without alexithymia. CONCLUSIONS: It is important to identify alexithymic patients with psoriasis in clinical practice as they experience a higher disease burden and have a lower ability to express their feelings.
Asunto(s)
Síntomas Afectivos/etiología , Costo de Enfermedad , Psoriasis/psicología , Adulto , Síntomas Afectivos/epidemiología , Estudios de Casos y Controles , Europa (Continente)/epidemiología , Femenino , Humanos , Masculino , Prevalencia , Psoriasis/epidemiología , Escalas de Valoración Psiquiátrica , Calidad de Vida , Factores de Riesgo , Índice de Severidad de la Enfermedad , Sudáfrica/epidemiologíaRESUMEN
BACKGROUND: TRANSIT (NCT01059773) compared immediate and gradual transition from methotrexate to ustekinumab in psoriasis patients via multiple measures, including patient-reported outcomes. OBJECTIVE: To evaluate patient perception of treatment benefits in TRANSIT. METHODS: A total of 489 psoriasis patients received ustekinumab, with immediate cessation of methotrexate (Arm 1) or 4 weeks' overlap with decreasing methotrexate dose (Arm 2). Ustekinumab was administered at weeks 0, 4, 16, 28 and 40. Dermatology Life Quality Index (DLQI), EuroQol 5-item (EQ-5D), visual analogue scale (VAS) valuation technique and patient benefit index (PBI) were employed. Mean global PBI and sub-scores were calculated from the sum of the benefit items weighted by their respective relevance at baseline. Patient-relevant benefit was defined as PBI ≥1 (scale: 0 [no benefit] to 4 [maximum benefit]). Correlations of global PBI with Psoriasis Area and Severity Index (PASI) and DLQI were examined. RESULTS: Relationships between PBI and clinical data were evaluable in 340 patients. The most important treatment goals at baseline included: 'be healed of all skin defects', 'have confidence in therapy', 'get better skin quickly' and 'regain control of the disease'. Benefit in PBI global score was achieved at week 4 by 93% of patients in Arm 1 and 91% in Arm 2. Global PBI scores increased in both Arms between weeks 4 and 52. Global PBI correlated weakly with PASI change from baseline (correlation coefficient range: -0.22 to -0.40), and moderately with DLQI (-0.29 to -0.54). Overall DLQI score was lower than baseline at all times; and the percentage of patients with an overall score of 0 or 1 increased with time. Correspondingly, EQ VAS scores increased with time. DLQI and EQ VAS results were similar between arms. CONCLUSIONS: Regardless of the strategy for transitioning from methotrexate, ustekinumab was associated with rapid and sustained improvement in patient-reported outcomes. PBI appears a suitable tool for assessing patient-relevant treatment benefits in psoriasis patients.
Asunto(s)
Fármacos Dermatológicos/uso terapéutico , Metotrexato/uso terapéutico , Psoriasis/tratamiento farmacológico , Calidad de Vida , Ustekinumab/uso terapéutico , Humanos , Psoriasis/fisiopatologíaRESUMEN
AIM: To identify the most likely metabolic disturbances and risk factors for stone formation in a group of patients with calcium oxalate urolithiasis, and to establish the relationship between the mineralogical composition of calculi and impaired excretion of inhibitors and promoters of stone formation. MATERIALS AND METHODS: Fifty patients with calcium oxalate urolithiasis were tested using a complex of physicochemical methods. Patients assessment included evaluation of quantitative mineralogical composition of calculi, daily urine pH profile and daily urinary excretion of urates, calcium, magnesium, oxalate, phosphate and citrate ions. RESULTS: The main mineralogical phase of the stones in over 80% of patients was calcium oxalate monohydrate; none of the patients had pure dihydrate stones. The most frequent metabolic disorders were hypocitraturia, hypercalciuria and hyperuricosuria. Predominant risk factors were excessive body weight and insufficient fluid intake. Only one patient had an idiopathic stone formation. It was established for the first time that patients with calcium oxalate stones, containing 10 or more mass percent of apatites had statistically significantly lower daily urinary calcium and oxalate excretion and simultaneously increased phosphate excretion. CONCLUSIONS: The study findings showed that patients with calculi based on calcium oxalate dihydrate should undergo testing for daily urinary excretion of calcium and citrate while pa-tients with calcium oxalate stones containing 10 or more mass percent of apatites should also be tested for daily phosphate excretion and urine pH-profile. Daily urinary citrate excretion was reduced in all study patients, and urate excretion was significantly increased, apparently due to an imbalanced diet and excessive intake of animal protein. Menopausal and postmenopausal women are at a particular risk due to low urinary citrate excretion and high urinary calcium excretion regardless of stone composition.
Asunto(s)
Oxalato de Calcio/análisis , Urolitiasis/metabolismo , Adulto , Factores de Edad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Cálculos Urinarios/química , Cálculos Urinarios/metabolismo , UrodinámicaRESUMEN
This paper focuses on developing and implementing a method of quantitative mineralogical analysis of urinary stones based on powder diffraction data analysis using 4 Topas (Bruker) software. Mineralogical composition of 100 urinary stones from urolithiasis patients living in Ivanovo region was examined. More than 70% of stones consisted of calcium oxalate monohydrate (COM) and calcium oxalate dihydrate (COD), and their mixtures with hydroxylapatite. Forty four percent of urinary stones consisted of one component (COM, uric acid (UA) or, less frequently, hydroxyapatite (HA); 56% of urinary stones comprised two, three or four components. The most common mineral was COM (more than 70% of cases), the rarest were calcium oxalate trihydrate (CT), brushite and newberrite. The most common combinations of minerals in mixed stones were COM+HA, COM+COD and COM+COD+HA. The texture, the surface composition and its changes in the course of chemolysis in different types of stones were examined using scanning electron microscopy (SEM) and X-ray microanalysis (XRM). Implications for using analytical chemical and physical techniques for the diagnosis and treatment of urolithiasis were discussed.
Asunto(s)
Oxalato de Calcio/metabolismo , Fosfatos de Calcio/metabolismo , Durapatita/metabolismo , Compuestos de Magnesio/metabolismo , Fosfatos/metabolismo , Ácido Úrico/metabolismo , Cálculos Urinarios/metabolismo , Femenino , Humanos , Masculino , Federación de Rusia/epidemiología , Cálculos Urinarios/epidemiologíaRESUMEN
We describe the applications of new cellular magnetic labeling method to endothelial progenitor cells (EPC), which have therapeutic potential for revascularization. Via their negative surface charges, anionic magnetic nanoparticles adsorb non-specifically to the EPC plasma membrane, thereby triggering efficient spontaneous endocytosis. The label is non-toxic and does not affect the cells' proliferative capacity. The expression of major membrane proteins involved in neovascularisation is preserved. Labeled cells continue to differentiate in vitro and to form tubular structures in Matrigel (an in vitro model of neovascularization). This process was followed in situ by using high-resolution MRI. Finally, we show that magnetic forces can be used to move magnetically labeled EPC in vitro and to modify their organization in Matrigel both in vitro an in vivo. Magnetic cell targeting opens up new possibilities for vascular tissue engineering and for delivering localized cell-based therapies.
Asunto(s)
Vasos Sanguíneos/crecimiento & desarrollo , Células Endoteliales/citología , Células Endoteliales/fisiología , Magnetismo , Células Madre Mesenquimatosas/citología , Células Madre Mesenquimatosas/fisiología , Ingeniería de Tejidos/métodos , Prótesis Vascular , Vasos Sanguíneos/citología , Diferenciación Celular , Proliferación Celular , Separación Celular/métodos , Células Cultivadas , Humanos , Micromanipulación/métodos , Neovascularización Fisiológica/fisiologíaRESUMEN
Certain agents of the proteoglycan nature possessing organ-specific rather than the species-specific antimitotic chalone activity have been obtained from the normal bovine spleen and thymus. The preparations obtained by the same method from the spleen and the thymus of animals affected by lympholeukemia and lymphosarcoma did not reveal the antimitotic activity; moreover, they were of high mitogenic organ-specific character. A connection between the mitogenic factor produced by lymphocytic cells and the bovine leukemia virus is possible.
Asunto(s)
Enfermedades de los Bovinos/fisiopatología , Sustancias de Crecimiento/farmacología , Leucemia Linfoide/veterinaria , Linfoma no Hodgkin/veterinaria , Bazo/efectos de los fármacos , Timo/efectos de los fármacos , Animales , Bovinos , Femenino , Inhibidores de Crecimiento/aislamiento & purificación , Inhibidores de Crecimiento/farmacología , Sustancias de Crecimiento/aislamiento & purificación , Virus de la Leucemia Bovina , Leucemia Linfoide/fisiopatología , Linfoma no Hodgkin/fisiopatología , Ratones , Ratones Endogámicos C57BL , Mitosis/efectos de los fármacos , Especificidad de Órganos/efectos de los fármacos , Proteoglicanos/aislamiento & purificación , Proteoglicanos/farmacología , Especificidad de la EspecieRESUMEN
Chalone-like proteoglycans from sheep and bovine thymus and spleen were shown to suppress cell proliferation in murine thymus or spleen. Their effect appeared to be organ-specific but not species-specific. Administration of the proteoglycans resulted in a decrease in the mitotic activity of thymus and spleen cells 24h (strain C57BL), three days (hybrids), four days (nude mice) or five days (highly cancerous strain C3H/He and white mongrel mice) after birth. These changes are probably due to genetic peculiarities of immune system formation in different mouse strains. The activity of chalone-like proteoglycans from spleen and thymus of 1-, 3- and 6-months old sheep was lower than that of adult sheep (two and five years old) indicating that the proteoglycan activity increases during ontogenesis.
Asunto(s)
Envejecimiento/efectos de los fármacos , Inhibidores de Crecimiento/farmacología , Proteoglicanos/farmacología , Bazo/efectos de los fármacos , Timo/efectos de los fármacos , Envejecimiento/metabolismo , Animales , Antineoplásicos , Bovinos , Genotipo , Inhibidores de Crecimiento/aislamiento & purificación , Linfocitos/efectos de los fármacos , Linfocitos/metabolismo , Ratones , Ratones Endogámicos C3H , Ratones Endogámicos C57BL , Mitosis/efectos de los fármacos , Proteoglicanos/aislamiento & purificación , Ovinos , Bazo/citología , Bazo/metabolismo , Timo/citología , Timo/metabolismoRESUMEN
The study was undertaken to examine the impact of experimental diabetes mellitus on the biotransformation of some drugs, their toxicity and hypoglycemic action, as well as on the biotransformation of endogenous testosterone and the androgenic status. The accelerated metabolism of both exogenous and endogenous substrates which occurred in diabetes mellitus caused a decrease in their biological activity.
Asunto(s)
Diabetes Mellitus Experimental/metabolismo , Glucuronatos/metabolismo , Xenobióticos/farmacocinética , Animales , Biotransformación , Glucemia/metabolismo , Relación Dosis-Respuesta a Droga , Masculino , Ratones , Fenolftaleína , Fenolftaleínas/farmacocinética , Ratas , Ratas Wistar , Testosterona/metabolismo , Factores de TiempoRESUMEN
Cyclic 3',5-AMP in vitro increased the activity of Na+, K+-ATPase, isolated from cortex and medulla of rabbit kidney. Maximal stimulating effect was observed in kidney cortex at 10(-6) M concentration and in medulla at 10(-4) M concentration of 3',5'-AMP. Under these conditions the enzymatic activity was increased by 24.6 +/- 4.1% and 27.9 +/- 7.7%, respectively. These data suggest that Na+, K+-ATPase, activated by cyclic 3',5'-AMP, is directly involved in the mechanism of Na+ transport in cells of osmoregulating organs.
Asunto(s)
Adenosina Trifosfatasas/metabolismo , AMP Cíclico/farmacología , Riñón/enzimología , Animales , Activación Enzimática/efectos de los fármacos , Corteza Renal/efectos de los fármacos , Corteza Renal/enzimología , Médula Renal/efectos de los fármacos , Médula Renal/enzimología , Potasio/farmacología , Conejos , Sodio/farmacologíaRESUMEN
The activity of gamma-glutamyl transferase (GGTF, EC 2.3.2.2) has been investigated in different brain structures (hemispheres, cerebellum, hippocamp, brain stem) of newborn, 3-8-, 15-, 21-30-day and adult rats and piping hare. In both animals, the activity of this enzyme in all the structures investigated increases during ontogenesis. Interspecific differences were found in the increase of the enzymic activity in different brain structures during ontogenesis as well as in the level of the activity in different structures in mature animals.
Asunto(s)
Encéfalo/enzimología , Lagomorpha/metabolismo , Mamíferos/metabolismo , gamma-Glutamiltransferasa/metabolismo , Animales , Animales Recién Nacidos , Encéfalo/crecimiento & desarrollo , Activación Enzimática , RatasRESUMEN
Development of hypoglycemia, a slight decrease in concentration of glucagon in blood as well as increase in activity of malate-and glucose-6-phosphate dehydrogenases in liver cytosol were detected in rats injected subcutaneously with nicotinamide at a dose of 31.25 mg/kg 6 hrs before decapitation. Increase of the single dose up to 125 mg/kg caused hypoglycemia, distinct increase in concentration of insulin and glucagon in blood plasma simultaneously with a pronounced inhibition of the enzymatic activity in liver tissue. Effect of nicotinamide on carbohydrate metabolism appears to have a dissimilar character depending on the drug dose: its small doses accelerated utilization and oxidation of glucose but did not affect the secretion of insulin and glucagon.
Asunto(s)
Glucemia/metabolismo , Metabolismo de los Hidratos de Carbono , Glucagón/metabolismo , Insulina/metabolismo , Niacinamida/farmacología , Animales , Glucagón/sangre , Glucosafosfato Deshidrogenasa/metabolismo , Insulina/sangre , Secreción de Insulina , Hígado/enzimología , Malato Deshidrogenasa/metabolismo , Masculino , NAD/metabolismo , NADP/metabolismo , Niacinamida/administración & dosificación , Ratas , Ratas EndogámicasRESUMEN
In experiments on rats subjected for 30 days to perform a graded muscular work (swimming) the influence produced by different levels of protein in the diet (6,18 and 30% by calorific value) on the accretion of body mass, physical work capacity, diurnal passage of total nitrogen, creatinine and creatine with urine was studied. At rest and following the maximum physical efforts the sugar, lactate and pyruvic acids levels were measured in the blood of rats. Food rations with low protein content (6% of the total caloricity), when used in conditions involving physical efforts, exerted an adverse effect on the growth, development and physical work capacity of the animals. The use of a protein-rich diet (30% by caloricity) did not show any substantial advantages over the standard one (18% of protein). In rats fed on diets with 18 and 30% of protein (in terms of caloricity) the body mass gain, physical work capacity and also the nature of changes in the content of lactate, pyruvate and sugar in the blood were the same.
Asunto(s)
Proteínas en la Dieta/administración & dosificación , Esfuerzo Físico , Deficiencia de Proteína/fisiopatología , Animales , Glucemia/análisis , Peso Corporal , Creatina/orina , Creatinina/orina , Dieta , Lactatos/sangre , Masculino , Nitrógeno/orina , Tamaño de los Órganos , Deficiencia de Proteína/metabolismo , Piruvatos/sangre , Ratas , Natación , Factores de TiempoRESUMEN
In research work involving participation of highly trained sportsmen-heavy athletes subject to studies was the effect of the proteinic product CII-11, developed at the Nutrition Institute of the AMS of the USSR, on the body mass gain, as well as on individual aspects, of the protein and catecholamines metabolism. Under the effect of the CII-11 intake for 7 days in an amount of 100.0 g per day all the sportsmen under examination demonstrated a gain in the body mass, growing diurnal passage of total nitrogen and urea with urine and reduced excretion of amino nitrogen. No changes in the ammonia and creatinine content in the diurnal urine occurred under the effect of the CII-11 product. The ingestion of the latter promoted activation of the mediator and hormonal members of the sympatico-adrenal system. The results of the CII-11 application in training rallies with participation of sportsmen-heavy athletes and members of the combined USSR team also bear witness to the favourable action of the product on the study aspects of the protein and biogenic amines metabolism, the body mass gains and also on the results of sporting events.
Asunto(s)
Proteínas en la Dieta/administración & dosificación , Medicina Deportiva , Deportes , Ritmo Circadiano , Dieta , Proteínas en la Dieta/metabolismo , Metabolismo Energético , Humanos , Nitrógeno/orina , Necesidades Nutricionales , Factores de Tiempo , U.R.S.S.RESUMEN
Data of a study on the factual nutrition, energy expenditures and individual indices of the nitrogen and lipids metabolism rates in students of a Physical Culture Institute of different sport specialties (heavy athletics, light athletics, wrestling, skying, cycling and rowing) are presented. Shortcomings and organization of the students' nutrition are considered and suggestions for its improvement are given.
Asunto(s)
Metabolismo Energético , Metabolismo , Fenómenos Fisiológicos de la Nutrición , Educación y Entrenamiento Físico , Adolescente , Adulto , Ingestión de Energía , Conducta Alimentaria/fisiología , Humanos , Masculino , Medicina Deportiva , Factores de Tiempo , U.R.S.S.RESUMEN
A novel two-step protocol for intracellular drug delivery has been evaluated in vitro. As a first step TO-PRO-3 (a cell-impermeable dye that displays a strong fluorescence enhancement upon binding to nucleic acids) encapsulated in thermosensitive liposomes was released after heating to 42°C. A second step consisted of ultrasound-mediated local permeabilization of cell membrane allowing TO-PRO-3 internalization observable as nuclear staining. Only the combination of two consecutive steps - heating and sonication in the presence of SonoVue microbubbles led to the model drug TO-PRO-3 release from the thermosensitive liposomes and its intracellular uptake. This protocol is potentially beneficial for the intracellular delivery of cell impermeable drugs that suffer from rapid clearance and/or degradation in blood and are not intrinsically taken up by cells.